Novo Nordisk announces plans to transform its approach to Research & Development

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious chronic diseases. To enable increased investment in transformational biological and technological innovation within both core and new therapy areas, approximately 400 employees will be laid off from R&D roles in Denmark and China.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news